ERAS
Erasca, Inc.Company Information
- Company Name
- Erasca, Inc.
- CIK
- CIK0001761918
- Category
- <br>Emerging growth company
- Ticker: Exchange
- ERAS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ERAS
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-05-21
- Last sale
- 2026-04-01
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 220,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 254,613,874
- Shares outstanding
- 311,336,806
- Ownership
- 81.78%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -11.58%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 43 | 47 | 74 | 70 | 66 | 70 | 68 | 69 | 173 | 77 | 93 | 113 | ||||||
| Marketable Securities Current | 226 | 197 | 202 | 218 | 235 | 234 | 231 | 250 | 236 | 221 | 219 | 184 | ||||||
| Prepaid Expense And Other Assets Current | 10 | 10 | 10 | 12 | 10 | 10 | 10 | 11 | 10 | 9 | 8 | 9 | ||||||
| Assets Current | 278 | 254 | 286 | 300 | 311 | 315 | 309 | 330 | 418 | 307 | 321 | 306 | ||||||
| Marketable Securities Noncurrent | 116 | 165 | 66 | 74 | 86 | 106 | 142 | 144 | 52 | - | 10 | 47 | ||||||
| Property Plant And Equipment Net | 12 | 13 | 13 | 14 | 15 | 16 | 16 | 17 | 18 | 21 | 22 | 23 | ||||||
| Operating Lease Right Of Use Asset | 27 | 28 | 29 | 30 | 31 | 32 | 32 | 33 | 34 | 37 | 38 | 39 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | ||||||
| Assets | 435 | 461 | 396 | 420 | 445 | 471 | 503 | 529 | 526 | 370 | 395 | 419 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 2 | 1 | 3 | 2 | 2 | 0 | 2 | 2 | 3 | 2 | 4 | ||||||
| Accrued Liabilities And Other Liabilities | 26 | 19 | 22 | 21 | 22 | 18 | 26 | 23 | 18 | 17 | 20 | 19 | ||||||
| Operating Lease Liability Current | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | ||||||
| Liabilities Current | 34 | 27 | 29 | 29 | 28 | 25 | 31 | 30 | 25 | 30 | 26 | 27 | ||||||
| Operating Lease Liability Noncurrent | 39 | 41 | 42 | 43 | 45 | 46 | 47 | 48 | 50 | 51 | 52 | 53 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Liabilities | 73 | 68 | 71 | 73 | 73 | 72 | 79 | 79 | 75 | 82 | 79 | 80 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,483 | 1,470 | 1,217 | 1,210 | 1,204 | 1,197 | 1,191 | 1,184 | 1,155 | 930 | 923 | 916 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | 1 | 1 | 0 | 1 | 0 | 2 | -0 | -0 | 0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -1,120 | -1,076 | -892 | -863 | -833 | -799 | -768 | -735 | -704 | -641 | -606 | -576 | ||||||
| Stockholders Equity | 362 | 394 | 325 | 348 | 372 | 400 | 423 | 450 | 451 | 288 | 317 | 339 | ||||||
| Liabilities And Stockholders Equity | 435 | 461 | 396 | 420 | 445 | 471 | 503 | 529 | 526 | 370 | 395 | 419 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | ||||||
| Common Stock Shares Issued | 313 | 311 | 284 | 284 | 284 | 283 | 283 | 283 | 273 | 151 | 151 | 151 | ||||||
| Shares Outstanding | 313 | 311 | 284 | 284 | 284 | 283 | 283 | 283 | 273 | 151 | 151 | 151 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialErasca, Inc. (ERAS) — SEC Financial Statements & Analysis
Erasca, Inc. (ERAS) is a pharmaceutical preparations company, incorporated in DE. Erasca, Inc. trades on Nasdaq as: ERAS. Erasca, Inc. (ERAS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Erasca, Inc. carries a market cap of $5.70B, a P/E ratio of -19.86x, a P/B ratio of 15.76x, an enterprise value of $5.66B, and an EV/EBITDA multiple of -18.89x. On profitability, it posts a Return on Equity (ROE) of -78.25%, a Return on Assets (ROA) of -65.25%, and a Return on Invested Capital (ROIC) of -96.79%. Per share, it reports EPS of $-0.92, diluted EPS of $-0.92, free cash flow per share of $-0.32, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 123.91% year-over-year and EPS growth of 103.79% year-over-year. On the balance sheet, it maintains a current ratio of 8.29x, a quick ratio of 8.01x, working capital of $244.87M, a debt-to-equity ratio of 0.20x, a debt ratio of 0.17, an interest coverage ratio of -19.42x, free cash flow of $-98.08M (TTM), and net debt of $-42.54M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.70B
- P/E TTM
- -19.86x
- EPS TTM
- $-0.92
- P/B TTM
- 15.76x
- ROE TTM
- -78.25%
- ROA TTM
- -65.25%
- Debt To Equity
- 0.20x
- Free Cash Flow TTM
- $-98.08M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Erasca, Inc. in?
Erasca, Inc. (ERAS) operates in the Pharmaceutical Preparations industry.
What exchange does ERAS trade on?
Erasca, Inc. (ERAS) trades on the Nasdaq.
Where is Erasca, Inc. incorporated?
Erasca, Inc. is incorporated in DE.
When was Erasca, Inc. (ERAS)'s most recent SEC filing?
Erasca, Inc. (ERAS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is ERAS's market cap?
Erasca, Inc. (ERAS) has a market capitalization of $5.70B as of 2026-06-30.
What is ERAS's EPS (earnings per share)?
Erasca, Inc. (ERAS)'s trailing twelve month EPS is $-0.92 as of 2026-06-30.
What is ERAS's ROE (return on equity)?
Erasca, Inc. (ERAS)'s trailing twelve month Return on Equity (ROE) is -78.25% as of 2026-06-30.
What is ERAS's ROA (return on assets)?
Erasca, Inc. (ERAS)'s trailing twelve month Return on Assets (ROA) is -65.25% as of 2026-06-30.
What is ERAS's ROIC (return on invested capital)?
Erasca, Inc. (ERAS)'s trailing twelve month Return on Invested Capital (ROIC) is -96.79% as of 2026-06-30.
What is ERAS's EV/EBITDA?
Erasca, Inc. (ERAS)'s trailing twelve month EV/EBITDA is -18.89x as of 2026-06-30.